| The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection M Rudwaleit, D Van Der Heijde, R Landewé, J Listing, N Akkoc, J Brandt, ... Annals of the rheumatic diseases 68 (6), 777-783, 2009 | 4495 | 2009 |
| EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update R Agca, SC Heslinga, S Rollefstad, M Heslinga, IB McInnes, MJL Peters, ... Annals of the rheumatic diseases 76 (1), 17-28, 2017 | 1384 | 2017 |
| Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial C Antoni, GG Krueger, K de Vlam, C Birbara, A Beutler, C Guzzo, B Zhou, ... Annals of the rheumatic diseases 64 (8), 1150-1157, 2005 | 951 | 2005 |
| Treatment recommendations for psoriatic arthritis CT Ritchlin, A Kavanaugh, DD Gladman, PJ Mease, P Helliwell, ... Annals of the rheumatic diseases 68 (9), 1387-1394, 2009 | 736 | 2009 |
| Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force JS Smolen, M Schöls, J Braun, M Dougados, O FitzGerald, DD Gladman, ... Annals of the rheumatic diseases 77 (1), 3-17, 2018 | 698 | 2018 |
| International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis J Braun, T Pham, J Sieper, J Davis, SJ Van der Linden, M Dougados, ... Annals of the rheumatic diseases 62 (9), 817-824, 2003 | 624 | 2003 |
| European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies L Gossec, JS Smolen, C Gaujoux-Viala, Z Ash, H Marzo-Ortega, ... Annals of the rheumatic diseases 71 (1), 4-12, 2012 | 593 | 2012 |
| What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical … AJB Wanders, RBM Landewé, A Spoorenberg, M Dougados, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2004 | 463 | 2004 |
| Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. A Spoorenberg, D van der Heijde, E de Klerk, M Dougados, K De Vlam, ... Outcome and disease activity in ankylosing spondylitis: an international study, 2003 | 457 | 2003 |
| Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. K De Vlam, H Mielants, C Cuvelier, F De Keyser, EM Veys, M De Vos The Journal of rheumatology 27 (12), 2860-2865, 2000 | 379 | 2000 |
| A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease … L Gossec, M de Wit, U Kiltz, J Braun, U Kalyoncu, R Scrivo, M Maccarone, ... Annals of the rheumatic diseases 73 (6), 1012-1019, 2014 | 376 | 2014 |
| Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery B Vander Cruyssen, E Munoz-Gomariz, P Font, J Mulero, K De Vlam, ... Rheumatology 49 (1), 73-81, 2010 | 320 | 2010 |
| The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project) PS Helliwell, O FitzGerald, J Fransen, DD Gladman, GG Kreuger, ... Annals of the rheumatic diseases 72 (6), 986-991, 2013 | 312 | 2013 |
| Three multicenter, randomized, double‐blind, placebo‐controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis A Deodhar, LS Gensler, J Sieper, M Clark, C Calderon, Y Wang, Y Zhou, ... Arthritis & Rheumatology 71 (2), 258-270, 2019 | 293 | 2019 |
| Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries A Boonen, D van der Heijde, R Landewé, A Spoorenberg, H Schouten, ... Annals of the rheumatic diseases 61 (5), 429-437, 2002 | 274 | 2002 |
| Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the … MC Genovese, K Kalunian, JE Gottenberg, N Mozaffarian, B Bartok, ... Jama 322 (4), 315-325, 2019 | 268 | 2019 |
| Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis RJU Lories, FP Luyten, K De Vlam Arthritis research & therapy 11, 1-8, 2009 | 265 | 2009 |
| Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double‐blind, placebo‐controlled study G Schett, J Wollenhaupt, K Papp, R Joos, JF Rodrigues, AR Vessey, ... Arthritis & Rheumatism 64 (10), 3156-3167, 2012 | 257 | 2012 |
| Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance … D Van der Heijde, A Kavanaugh, DD Gladman, C Antoni, GG Krueger, ... Arthritis & Rheumatism 56 (8), 2698-2707, 2007 | 235 | 2007 |
| Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial A Kavanaugh, GG Krueger, A Beutler, C Guzzo, B Zhou, LT Dooley, ... Annals of the rheumatic diseases 66 (4), 498-505, 2007 | 217 | 2007 |
Rik LoriesKU LeuvenVerified email at uz.kuleuven.be
